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Abstract
Background: Vasculogenic mimicry (VM) was increasingly recognized as a form of aggressive
melanoma acquiring blood supply. Genistein had attracted much attention as a potential anticancer
agent. Therefore, we examined the effect of Genistein on VM in human uveal melanoma cells.
Methods: VM structure was detected by periodic acid-Schiff (PAS) staining for uveal melanoma
C918 cells cultured on the three-dimensional type I collagen gels after exposed to Genistein. We
used reverse transcription polymerase chain reaction (RT-PCR) and Western Blot analysis to
examine the effect of Genistein on vascular endothelial cadherin (VE-cadherin) mRNA and protein
expression. The nude mice models of human uveal melanoma C918 cells were established to assess
the number of VM using immunohistochemical and PAS double-staining.
Results: Genistein inhibited the survival of C918 cells in vitro. The ectopic model study showed
that VM in tumor tissue sections were significantly reduced by Genistein in vivo. In vitro, the VM
structure was found in control, 25 and 50 μM Genistein-treatment groups but not in 100 and 200
μM. RT-PCR and Western Blot showed that 100 and 200 μM concentration of Genistein could
significantly decrease VE-cadherin mRNA and protein expression of C918 cells compared with
control (P < 0.05). However, the 25 and 50 μM Genistein slightly decreased the VE-cadherin level
in vitro (P > 0.05).
Conclusion: Genistein inhibits VM formation of uveal melanoma cells in vivo and in vitro. One
possible underlying molecular mechanism by which Genistein could inhibit VM formation of uveal
melanoma is related to down-regulation of VE-cadherin.
Background
Malignant tumor growth, progression, and metastasis
depend on adequate blood supply [1]. Much attention
has been focused on angiogenesis which is known as the
sprouting of new vessels from existing microvessels. The
traditional anticancer treatment is targeting the vascular
and endothelial cells [2,3]. In 1999, Maniotis and co-
workers introduced the concept of vasculogenic mimicry
(VM), a new mechanism by which aggressive melanoma
may acquire a blood supply [4]. VM channels are pat-
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terned networks of interconnected loops of periodic acid-
Schiff (PAS)-positive extracellular matrix forming by
aggressive melanoma tumor cells instead of endothelial
cells. Moreover, it is correlated with poor prognosis in
patients with tumors [4] and has been described in several
other aggressive tumor types [5-8]. Uveal melanoma, the
most common primary intra-ocular tumor in adults, has
been widely concerned as the purely hematogenous [9].
Nearly 50% of uveal melanoma patients die from meta-
static melanoma [10]. However, no effective therapeutic
modalities are available for preventing metastases or
improving the survival rate of uveal melanoma patients.
Genistein is a predominant isoflavone in soybeans and
has been shown to inhibit the invasion and growth of var-
ious cancer cells including prostate, breast, lung, head and
neck cancer [11-14]. The anticancer mechanism of Genis-
tein has been illustrated to inhibit angiogenesis both in
vivo and in vitro [15]. Our previous work also found that
Genistein was capable to inhibit ocular neovasculariza-
tion through suppression of vascular endothelial growth
factor (VEGF), hypoxia inducible factor 1 (HIF 1) and
basic fibroblast growth factor (bFGF) expression [16-19].
Genistein inhibit endothelial cells proliferation. Moreo-
ver, melanoma cells could imitate endothelial cells to
form VM channels and expressed some endothelial-asso-
ciated genes, including vascular endothelial cadherin (VE-
cadherin, a calcium-dependent adhesion molecule).
Therefore, this study was performed to evaluate the effect
of Genistein on the VM channels formation of highly
aggressive melanoma cells. In addition, it has been indi-
cated that VE-cadherin plays a critical role in the forma-
tion of melanoma VM [20,21]. We also examined the
influence of Genistein on VE-cadherin level and explored
the underlying molecular mechanisms of VM.
Materials and methods
Drug
Genistein was purchased from Sigma (St. Louis, Missouri,
USA) and dissolved in dimethylsulfoxide (DMSO) at the
concentration of 200 × 103 μM. Then it was diluted with
RPMI 1640 to the desired concentration. Final concentra-
tion of DMSO in cell culture medium was 0.1% (v/v). The
medium containing 0.1% DMSO only served as control.
Cell culture
The highly aggressive C918 and poorly aggressive OCM-
1A human uveal melanoma cell lines were generously
supplied by Prof. Elisabeth A Seftor (Children's Memorial
Research Center, Chicago, IL). The cells were maintained
in RPMI 1640 (Invitrogen) supplemented with 10% fetal
bovine serum and 0.1% gentamicin sulfate at 37°C in an
atmosphere of 5% CO2. After treatment with Genistein,
cell proliferative activity was determined by the MTT (3-
[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bro-
mide) assay.
Three-dimension culture and PAS-staining
Three-dimensional type I collagen gels were produced as
follows [22]: Fifty μl of type I collagen (3.02 mg/ml; BD
Bioscience, Bedford, MA) were dropped onto 18-mm
glass coverslips in six-well tissue culture plate. Absolute
ethanol was added to each well, and the collagen was
allowed to polymerize for 5 min at room temperature.
After a wash with PBS, 1 × 106 C918 cells or OCM-1A cells
were plated onto the three-dimensional type I collagen
gels to analyze the ability of the cells to engage in VM.
After 48h, the cells were fixed with 4% formaldehyde in
PBS for 10 min. To identify the matrix-associated pat-
terned networks of uveal melanoma, coverslips contain-
ing three-dimensional cultures were stained with PAS,
omitting hematoxylin counterstaining [4]. Different con-
centrations of Genistein (0, 25, 50, 100, and 200 μM) was
added to the cells to observe the effect of Genistein on VM.
Animal model and CD34-PAS dual staining
All animal experiments were approved by the local animal
ethics committee. Six week old female BALB/C nu/nu
mice were purchased from Vital River Laboratory Animal
Technology (Beijing, China). All experiments were per-
formed in accordance with the official recommendations
of the Chinese Community Guidelines. The xenografts
were established using C918 cells [23], which were resus-
pended at a density of 1 × 107/ml. The suspension (0.1
ml/10 g body weight) was injected subcutaneously into
the nude mice. After 6 days, tumor nodules were palpable.
Then the mice were randomly assigned into control and
Genistein groups: control (n = 5), injected intraperito-
neally with 1% DMSO/day; Genistein (n = 5), injected
intraperitoneally with Genistein 75 mg/kg/day. The treat-
ment was continued every day for 30 days. At the end,
mice were sacrificed by cervical decapitation and the
tumors were removed and weighed. C918 xenograft spec-
imens were fixed in 10% neutral buffered formalin and
paraffin-embedded. Paraffin-embedded specimens were
cut into serial 5-μm sections. And the sections were depar-
affinized, rehydrated, and subjected to immunohisto-
chemical and PAS double-staining. The
immunohistochemistry was conducted with monoclonal
mouse antibodies to the endothelium marker CD34 (1:50
dilution, Beijng, Zhong Shan Goldenbridge) to identify
endothelium. DAB chromogen was used for the immuno-
histochemistry. CD34 staining helped to distinguish the
PAS-positive network of VM from endothelium-lined
micro vessels. Tissues were stained with PAS to identify
the matrix-associated vascular channels of uveal
melanoma. Quantification of VM was performed as fol-
low [24]: The CD34-PAS dual staining sections were
viewed at × 400. The channels defined as VM were lined
by PAS-positive material with red cells in the center of the
channels, but not lined by CD34-positive endothelial
cells. The mean VM count of ten areas was calculated as
the VM density (VMD) respectively for each section. TheJournal of Experimental & Clinical Cancer Research 2009, 28:124 http://www.jeccr.com/content/28/1/124
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mean VMD from 5 xenograft specimens in the Genistein
and control groups were obtained as the final VMD count.
Semiquantitative RT-PCR analysis
The mRNA expression of VE-cadherin in C918 cells was
analyzed by reverse transcription polymerase chain reac-
tion (RT-PCR). At the end of Genistein treatment, total
RNA from C918 and OCM-1A cells cultured on a type I
collagen three-dimensional matrix was extracted using
Trizol reagent (Invitrogen) as the manufacturer's protocol.
The first-strand cDNA was synthesized from 3 μg of RNA
by standard reverse transcription (RT) methods, using M-
MuLV reverse transcriptase (MBI Fermentas, Vilnius,
Lithuania) and oligt (d) T primer according to the manu-
facturer's instructions. Specific primers (forward: 5'-CAC-
CGGCGCCAAAAGAGAGA-3'; reverse: 5'-CTGGTTTTC
CTTCAGCTGGAAGTGGT-3') and (forward: 5'-TGAAG-
GTCGGAGTCAACGGATTTGGT-3'; reverse: 5'-CATGT-
GGGCCATGAGGTCCACCAC-3') were used to amplify
the VE-cadherin sequence and GAPDH [22]. PCR amplifi-
cation was performed using the T1 Thermocycler (Biome-
tra, Goettingen, Germany) as follows: 1 cycle of 94°C for
1 min; 25-30 cycles of 94°C for 1 min, 68°C for 2.5 min,
and 72°C for 1 min; and 1 cycle of 72°C for 5 min [22].
Electrophoresis of the PCR product was performed on a
2% agarose gel containing 0.5 μg/ml ethidium bromides
using 6 μl of the reaction. Results were normalized by the
ratio of band density of specific product to GAPDH. The
RT-PCRs were performed three times with independently
derived samples.
Western blot analysis
At the end of Genistein treatment, cells were rinsed twice
with ice-cold PBS and then lysed with ice-cold lysis buffer
(50 mM of Tris-HCl, pH7.5, 150 mM of NaCl, 0.5% NP-
40, 1 mM of EDTA, 0.2 mM of PMSF, 100 μl/ml of protei-
nase inhibitor Aprotinin) for 30 min. The cell lysates were
centrifuged at 12,000 g for 10 min at 4°C, and the super-
natant was collected and stored at -80°C until use. Protein
concentration was confirmed by using the Bradford assay.
Equal amounts of protein were mixed with SDS sample
buffer (0.125 M Tris-HCl, pH 6.8, 10% glycerol, 2% β-
mercaptoethanol, 2% SDS and 0.1% bromophenol blue)
and boiled for 5 min. Then samples were electrophoresed
on SDS-PAGE and transferred to PVDF membrane using a
standard protocol. The membrane was blocked in 5%
non-fat dried milk for 2 h, rinsed and then incubated with
antibody to human VE-cadherin (R&D Systems) 1 h at
37°C and overnight at 4°C. Excess antibody was then
removed by washing the membranes in TBST (TBS con-
taining 0.01% Tween 20) and membranes were incubated
1 h at 37°C with HRP-conjugated secondary antibodies.
After being washed in TBST, bands were visualized by an
enhanced chemiluminescence (ECL, Amersham Pharma-
cia Biotech) system and exposed to radiography film.
Molecular weight was determined by comparison with
molecular weight markers.
Statistics
Statistical analyses were performed using software from
SPSS for Windows 13.0 (SPSS Inc., Chicago, IL, USA). All
data were described as mean ± SEM. To analyze the data
statistically, we performed Student's t-test with analysis.
Differences were considered significant when P < 0.05.
Results
VM structure in C918 cells and OCM-1A cells
As showed in Figure 1, the VM structure was found in
highly aggressive uveal melanoma C918 cells cultured in
three-dimensional type I collagen gels but not in poorly
aggressive uveal melanoma OCM-1A cells. Moreover,
C918 cells expressed the VE-cadherin and the contrary
result appeared in OCM-1A cells.
Effect of Genistein on the human uveal melanoma C918 
cells growth
After treatment for up to 48 h with various concentrations
of Genistein (10, 25, 50, 100, 200 μM), the result dis-
played Genistein significantly decreased the cell survival
in a dose-dependent manner (Figure 2). The cell mor-
phology was observed under a phase contrast microscope
following treatment with Genistein. Genistein signifi-
cantly induced the spindle-cell morphology in C918 cells.
At the final concentrations of 100 and 200 μM, Genistein
leaded to 56.3 and 78.4% reductions in number of C918
cells, respectively. The control group was set at 100%.
Comparison of VM channels and the VE-cadherin mRNA  level between C918 cells and OCM-1A cells Figure 1
Comparison of VM channels and the VE-cadherin 
mRNA level between C918 cells and OCM-1A cells. 
(A) OCM-1A cells cultured in three-dimensional type I colla-
gen gels do not form the VM network structure. (B) C918 
cells have the ability to form the VM. (C) VE-cadherin was 
expressed by C918 cells but not OCM-1A cells. (A and B, 
Magnification: × 200)Journal of Experimental & Clinical Cancer Research 2009, 28:124 http://www.jeccr.com/content/28/1/124
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Evaluation of VM channel formation after Genistein 
treatment in vitro
After 48 h exposure to different concentrations Genistein,
the ability of C918 melanoma cells to form VM channels
was investigated using PAS staining (Figure 3). At the 25
μM and 50 μM of Genistein treatment groups, C918 cells
formed fewer VM matrix-association channels than con-
trol. However, the groups treated with higher concentra-
tions of Genistein (100 and 200 μM) did not form the VM
channels.
The regulation of microcirculation patterns by Genistein in 
vivo
In order to further investigate the role of Genistein on VM
formation of human uveal melanoma, we established
ectopic model of human uveal melanoma in athymic
nude mice. The result showed Genistein significantly
inhibited the growth of xenograft in vivo. The inhibition
rate of tumor growth for 75 mg/kg/day Genistein was
27.5% compared with the control group. VM in tumor tis-
sue sections was evaluated (Figure 4) VM channels in
C918-derived xenografts were significantly reduced in
Genistein group compared with the control (P < 0.05)
(Table 1).
The influence of Genistein on the mRNA expression of VE-
cadherin
Semiquantitative RT-PCR was used to examine the VE-
cadherin mRNA expression in C918 cells with different
concentrations of Genistein. As demonstrated in Figure 5,
VE-cadherin levels were significantly decreased in 100 and
200 μM Genistein-treated groups (P < 0.05 and P < 0.01,
respectively). However, the 25 and 50 μM Genistein-
treated groups slightly down regulated the VE-cadherin
levels and no had statistics significance.
The influence of Genistein on the protein expression of VE-
cadherin
The VE-cadherin protein expression was assayed in C918
cells treated with different concentrations of Genistein
(Figure 6). We found that 100 and 200 μM concentrations
of Genistein could significantly inhibit VE-cadherin pro-
tein expression (P < 0.05). The levels were decreased to
55.9% ± 13.9% and 49.2% ± 11.2%, respectively, of that
untreated with Genistein. However, the 25 and 50 μM
Genistein slightly decreased the VE-cadherin protein (P >
0.05).
Discussion
As a new tumor microcirculation pattern, VM differs from
classically described endothelium-dependent angiogen-
esis. It is formed by aggressive melanoma tumor cells.
Therefore, the VM channels maybe an additional target to
treat solid tumors [3,25]. It has been demonstrated that
several drugs could inhibit VM [22,26-28]. In this study,
we found that Genistein could inhibit VM formation of
uveal melanoma cells in vivo and in vitro.
Genistein has strong anticancer activities, including the
inhibition of cell proliferation and angiogenesis, the
Effect of Genistein on of human uveal melanoma C918 cells  growth Figure 2
Effect of Genistein on of human uveal melanoma 
C918 cells growth. Proliferative activity of C918 cells was 
determined by the MTT assay after incubation for 48 h with 
Genistein (0-200 μM). **P < 0.01 vs. control.
The effect of Genistein on the vasculogenic mimicry of human uveal melanoma C918 cells on 3-D collagen I cultures Figure 3
The effect of Genistein on the vasculogenic mimicry of human uveal melanoma C918 cells on 3-D collagen I 
cultures. PAS-stained images of C918 cells cultured on three-dimensional collagen I for 48 h in medium with different concen-
trations of Genistein. (A) control; (B) 25 μM Genistein; (C) 50 μM Genistein; (D) 100 μM Genistein; (E) 200 μM Genistein. At 
treatment groups with 25 μM and 50 μM concentrations of Genistein, C918 cells formed fewer VM matrix-association chan-
nels than do control. However, the groups treated with higher concentrations of Genistein (100 and 200 μM) did not form the 
VM channels. (Magnification: × 200)Journal of Experimental & Clinical Cancer Research 2009, 28:124 http://www.jeccr.com/content/28/1/124
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induction of differentiation and apoptosis [29]. Numer-
ous studies have reported the inhibitory effect of Genis-
tein toward different tumor types. Moreover, Genistein
was shown to inhibit growth of B16 mice melanoma cell
in vivo and in vitro [30,31]. Our results suggested that
Genistein inhibited the growth of C918 highly aggressive
uveal melanoma cells in dose-dependent manner. The
average quantity of VM in xenografts sections were signif-
icantly reduced in Genistein treatment group compared
with the control. These results indicated that Genistein
may have effect on VM formation of human uveal
melanoma.
Further analysis suggested that one possible molecular
mechanism of Genistein inhibited VM formation was
related to down-regulation of VE-cadherin. Hendrix et al.
found the expression of VE-cadherin by highly aggressive
melanoma tumor cells leads to their ability to mimic
endothelial cells and form VM in three-dimensional cul-
ture [20]. They thought VE-cadherin plays a critical role in
the formation of VM by melanoma [20]. Hess et al. indi-
cated VE-cadherin was involved in the initial signaling
and regulation of the VM process. In present study, we
indicated that the expression of VE-cadherin of C918 cells
was lower in the Genistein treatment groups than the con-
trol group. In accordance with our results, previous stud-
ies also proved that Genistein was capable of reducing the
expression of VE-cadherin [32,33]. High concentrations
of Genistein (100, 200 μM) significantly reduced the
expression of VE-cadherin and completely inhibited the
formation of VM. Accordingly, Hendrix et al. also found
no networks were formed when VE-cadherin expression
was down-regulated [20]. In addition, recent study also
Table 1: Comparison VM channels of xenograft specimens in the 




Genistein (n = 5) 0.67 ± 0.17 P<0.05
Control (n = 5) 1.5 ± 0.23
*Genistein group, Genistein was administered intraperitoneally (75 
mg/kg/day) for 30 days. Control group received equivalent DMSO. 
Tumors were conducted immunohistochemical (CD34) and PAS 
double-staining to distinguish between endothelium-dependent 
microvessel and vasculogenic mimicry.
# vasculogenic mimicry density.
CD34 and PAS double staining on the C918 human uveal  melanoma xenograft sections Figure 4
CD34 and PAS double staining on the C918 human 
uveal melanoma xenograft sections. (A) Control; (B) 75 
mg/kg/day Genistein group; VM channel (arrow) is lined by 
PAS-positive materials and there are red cells in the center of 
the channels. (Magnification: × 400)
Effect of Genistein on C918 cells VE-cadherin mRNA expres- sion Figure 5
Effect of Genistein on C918 cells VE-cadherin mRNA 
expression. (A) The expression of VE-cadherin mRNA in 
C918 cells was examined by RT-PCR at 48 h after different 
concentration Genistein pretreatment (0, 25, 50, 100, 200 
μM). (B) The results of VE-cadherin mRNA were expressed 
after normalized by β-actin. Data represent means ± S.E.M 
from three separate experiments. *P < 0.05, **P < 0.01 vs. 
control.
Effect of Genistein on C918 cells VE-cadherin protein  expression Figure 6
Effect of Genistein on C918 cells VE-cadherin protein 
expression. (A) The expression of VE-cadherin protein in 
C918 cells was examined by western blot at 48 h after differ-
ent concentration Genistein pretreatment (0, 25, 50, 100, 
200 μM). (B) The results of VE-cadherin protein were 
expressed after normalized by β-actin. The values were 
means ± S.E.M. n = 3. *P < 0.05 vs. control.Journal of Experimental & Clinical Cancer Research 2009, 28:124 http://www.jeccr.com/content/28/1/124
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suggested VM could be regulated through influencing the
endothelium and epithelium-specific genes expression
including VE-cadherin [34]. Consequently, we supposed
the effect of Genistein on the formation of human uveal
melanoma VM was mediated, at least partially, through
reduction of VE-cadherin expression.
In addition, Genistein has been reported to inhibit angio-
genesis in vivo and in vitro. Physiological connections
between tumor cell VM and angiogenesis microcircula-
tion have been demonstrated [35-39]. Thus, the decrease
of angiogenesis may affect the VM channels.
Conclusion
This study shows that Genistein could effectively inhibit
the VM formation of C918 human uveal melanoma in
vivo and in vitro. One of the mechanisms that Genistein
inhibits VM is associated with down regulation of VE-cad-
herin. Our present study may provide preliminary evi-
dence for future and wider research. Therefore,
substantially more studies are needed to define the
actions of Genistein on VM and find the effective thera-
peutic strategies of uveal melanoma and other cancers
related to VM.
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